Pfizer Inc. (NYSE:PFE) Hits New 52-Week High After Dividend Declaration – (PFE, GSK, MRK, ABT)
Pfizer Inc. (NYSE:PFE) hit new high on Friday after it declared that its Board of Directors has provided an approval for a $0.22 third-quarter 2012 dividend on the company`s common equity, due September 5, 2012, to owners as of record at the closing bell on August 3, 2012.
On Thursday, Reuters had reported that Nestle SA is holding talks with banks related to raising a new EUR7 billion ($8.7 billion) syndicated debt to help provide funding for its $11.85 billion acquisition of Pfizer, Inc.’s Nutrition.
Back in April, Nestle had said the takeover would be fully debt-financed through internal cash resources, existing facilities and the bond markets. The new debt would provide the company sufficient liquidity until the transaction is approved, which is expected to be in the first quarter of 2013, if the purchase goes ahead.
Pfizer Inc (NYSE:PFE) total value after the recent close was $172.23 billion and the enterprise value according to yahoo data was $183.90 billion. The previous 12 month price to sales ratio was 2.54. The company showed 12.54% as a profit margin in the last twelve months and an operating margin at 18.39%. Return on equity was 9.56% for the last twelve months. Return on assets was 4.37%.
Taking a look at some other competitors, the total value of GlaxoSmithKline plc (ADR) (NYSE:GSK) in the stock market was $113.06 billion and the takeover value of the company was $126.83 billion. The last twelve month price to sales ratio for the company was 2.61. It had a 19.18% as profit margin in the last twelve months and an operating margin at 28.45%. Return on assets was 12.63%
The total value of Merck & Co., Inc (NYSE:MRK) after the latest trading session was $126.99 billion and their enterprise value was $129.58 billion. The prior 52 week price to sales ratio was 2.57. The company recorded a profit margin of 14.71% for the prior 12 months and had an operating margin of 16.83%. Return on equity for this stock was 12.73% while return on assets appeared at 6.71%.
Abbott Laboratories (NYSE:ABT) market capitalization after the most recent trading session was $101.44 billion and the enterprise value was $108.56 billion. Price to sales ratio for the prior 52 weeks was 2.52.